DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)

作者：Logan Gemma E; Mor Vaknin Nirit; Braunschweig Till; Jost Edgar; Schmidt Pia Verena; Markovitz David M; Mills Ken I; Kappes Ferdinand; Percy Melanie J^*

来源：Blood Cells, Molecules, and Diseases, 2015, 54(1): 123-131.

DOI：10.1016/j.bcmd.2014.07.009

• DEK
• Acute Myeloid Leukemia
• Translocation t(6
• 9)
• Hematopoiesis
• Leukemagenesis

DEK is important in regulating cellular processes including proliferation, differentiation and maintenance of stem cell phenotype. The translocation t(6;9) in Acute Myeloid Leukemia (AML), which fuses DEK with NUP214, confers a poor prognosis and a higher risk of relapse. The over-expression of DEK in AML has been reported, but different studies have shown diminished levels in pediatric and promyelocytic leukemias. This study has characterized DEK expression, in silico, using a large multi-center cohort of leukemic and normal control cases. Overall, DEK was under-expressed in AML compared to normal bone marrow (NBM). Studying specific subtypes of AML confirmed either no significant change or a significant reduction in DEK expression compared to NBM. Importantly, the similarity of DEK expression between AML and NBM was confirmed using immunohistochemistry analysis of tissue mircorarrays. In addition, stratification of AML patients based on median DEK expression levels indicated that DEK showed no effect on the overall survival of patients. DEK expression during normal hematopoiesis did reveal a relationship with specific cell types implicating a distinct function during myeloid differentiation. Whilst DEK may play a potential role in hematopoiesis, it remains to be established whether it is important for leukemagenesis, except when involved in the t(6;9) translocation.

• 出版日期2015-1